Novavax Statistics
Share Statistics
Novavax has 161.97M
shares outstanding. The number of shares has increased by 14.56%
in one year.
| Shares Outstanding | 161.97M |
| Shares Change (YoY) | 14.56% |
| Shares Change (QoQ) | 0.41% |
| Owned by Institutions (%) | 64.11% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 8,984 |
| FTD / Avg. Volume | 0.14% |
Short Selling Information
The latest short interest is 42.33M, so 26.14% of the outstanding
shares have been sold short.
| Short Interest | 42.33M |
| Short % of Shares Out | 26.14% |
| Short % of Float | 26.23% |
| Short Ratio (days to cover) | 6.4 |
Valuation Ratios
The PE ratio is -6.53 and the forward
PE ratio is 11.26.
Novavax's PEG ratio is
0.08.
| PE Ratio | -6.53 |
| Forward PE | 11.26 |
| PS Ratio | 1.79 |
| Forward PS | 2.3 |
| PB Ratio | -1.96 |
| P/FCF Ratio | -12.2 |
| PEG Ratio | 0.08 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Novavax.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.98,
with a Debt / Equity ratio of -0.37.
| Current Ratio | 0.98 |
| Quick Ratio | 0.97 |
| Debt / Equity | -0.37 |
| Debt / EBITDA | -2.13 |
| Debt / FCF | -2.3 |
| Interest Coverage | -12.4 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $716,556.72 |
| Profits Per Employee | $-196,952.73 |
| Employee Count | 952 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 23.17 |
Taxes
| Income Tax | 10.88M |
| Effective Tax Rate | -6.16% |
Stock Price Statistics
The stock price has increased by -53.72% in the
last 52 weeks. The beta is 3.21, so Novavax's
price volatility has been higher than the market average.
| Beta | 3.21 |
| 52-Week Price Change | -53.72% |
| 50-Day Moving Average | 6.85 |
| 200-Day Moving Average | 9.33 |
| Relative Strength Index (RSI) | 44.11 |
| Average Volume (20 Days) | 6,480,518 |
Income Statement
In the last 12 months, Novavax had revenue of 682.16M
and earned -187.5M
in profits. Earnings per share was -1.23.
| Revenue | 682.16M |
| Gross Profit | 479.42M |
| Operating Income | -248.93M |
| Net Income | -187.5M |
| EBITDA | -108.04M |
| EBIT | -156.54M |
| Earnings Per Share (EPS) | -1.23 |
Full Income StatementBalance Sheet
The company has 530.23M in cash and 230.42M in
debt, giving a net cash position of 299.81M.
| Cash & Cash Equivalents | 530.23M |
| Total Debt | 230.42M |
| Net Cash | 299.81M |
| Retained Earnings | -5.01B |
| Total Assets | 1.29B |
| Working Capital | 445.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -87.26M
and capital expenditures -13.06M, giving a free cash flow of -100.32M.
| Operating Cash Flow | -87.26M |
| Capital Expenditures | -13.06M |
| Free Cash Flow | -100.32M |
| FCF Per Share | -0.66 |
Full Cash Flow StatementMargins
Gross margin is 70.28%, with operating and profit margins of -36.49% and -27.49%.
| Gross Margin | 70.28% |
| Operating Margin | -36.49% |
| Pretax Margin | -25.89% |
| Profit Margin | -27.49% |
| EBITDA Margin | -15.84% |
| EBIT Margin | -36.49% |
| FCF Margin | -14.71% |
